The ALIVER programme was designed to evaluate a novel approach to treating patients with acute-on chronic liver failure (ACLF) using a novel dialysis device, DIALIVE™. Its design is based on the understanding that albumin is destroyed, in patients with liver failure and allows removal and replacement of albumin and removal of DAMPs and PAMPS.
During 2020 the randomised controlled clinical trial of Dialive™ in adult patients with ACLF was completed and data analysis started. All indicates that Dialive™ treated patients experience an improvement of biomarkers, thought to be associated with the cytokine storm and organ failure in ACLF. If confirmed, it will mean that patients on Dialive™ show statistically significant benefits, compared to the control arm, ten days after the start of the treatment protocol of three to five sessions of eight to 12 hours each. Yaqrit Discovery Ltd., a spin off company from University College London, where DIALIVE was discovered will perform the next phase of clinical trials so that, the device can start to save lives of ACLF patients.